[2]
Garre-Olmo, J. Epidemiology of Alzheimer’s disease and other dementias. Rev. Neurol., 2018, 66(11), 377-386.
[25]
Boeddrich, A.; Babila, J.T.; Wiglenda, T. The anti-amyloid compound DO1 decreases plaque pathology and neuroinflammation-related expression changes in 5xFAD transgenic mice. Cell Chem. Biol., 2018.
[32]
Santa-Maria, I; Varghese, M; Ksiezak-Reding, H Paired helical filaments from Alzheimer's disease brain induce intracellular accumulation of tau in aggresomes., J. Biol. Chem., 2012, jbc-M111.
[33]
Dolan, P.J.; Johnson, G.V. The role of tau kinases in Alzheimer’s disease. Curr. Opin. Drug Discov. Devel., 2010, 13(5), 595-603.
[36]
Huynh, T.P.; Davis, A.A.; Ulrich, J.D. Apolipoprotein E and Alzheimer Disease: The influence of apoE on amyloid-β and other amyloidogenic proteins. J. Lipid Res., 2017,
R075481.
[39]
Zhao, J; Fu, Y; Liu, CC Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the RXR/RAR pathway. J. Biol. Chem., 2014, jbc-M113.
[43]
Elfawy, H.A.; Das, B. Crosstalk between mitochondrial dysfunction, oxidative stress, and age-related neurodegenerative disease: etiologies and therapeutic strategies. Life Sci., 2018.
[55]
Siddiqui, SS; Springer, SA; Verhagen, A The Alzheimer's Disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool. J Biol Chem., 2017, jbc-M117.
[60]
Korábečný, J.; Nepovimová, E.; Cikánková, T. Newly developed drugs for Alzheimer’s disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission. Neuroscience, 2017.
[91]
Kounnas, M.Z.; Lane-Donovan, C.; Nowakowski, D.W. NGP 555, a g-secretase modulator, lowers the amyloid biomarker, Ab42, in cerebrospinal fluid while preventing Alzheimer’s disease cognitive decline in rodents. Alzheimers Dement., 2016, 10.
[103]
Chau, S.A.; Liu, C.S.; Ruthirakuhan, M. Pharmacotherapy of dementia; Mental Health and Illness of the Elderly, 2017, pp. 1-26.
[106]
Xu, Y; Yang, M; Zhang, HT A selective phosphodiesterase 4D inhibitor BPN14770 reverses beta amyloid-induced memory impairment in humanized PDE4D mice. FASEB J, 2019, 33(1_supplement), 806-4.
[109]
Zhou, B; Rothlein, R; Shen, J. TTP4000, a soluble fusion protein inhibitor of Receptor for Advanced Glycation End Products (RAGE) is an effective therapy in animal models of Alzheimer’s disease, 2013, pp. 803-1.
[116]
Panarsky, R.; Luques, L.; Weinstock, M. Anti-inflammatory effects of ladostigil and its metabolites in aged rat brain and in microglial cells. J. Neuroimmune Pharmacol., 2012, 792, 488-498.
[129]
Lopez Lopez, C.; Caputo, A.; Liu, F.; Riviere, M.E.; Rouzade-Dominguez, M.L.; Thomas, R.G.; Langbaum, J.B.; Lenz, R.; Reiman, E.M.; Graf, A.; Tariot, P.N. The Alzheimer’s Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer’s Disease. J. Prev. Alzheimers Dis., 2017, 4(4), 242-246.
[133]
Amani, M.; Shokouhi, G.; Salari, A.A. Minocycline prevents the development of depression-like behavior and hippocampal inflammation in a rat model of Alzheimer’s disease. Psychopharmacology (Berl.), 2018, 4, 1-2.
[137]
Duggan, KC; Walters, MJ; Musee, J Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug, naproxen., J. Biol. Chem., 2010, jbc, M110.
[140]
Guo, C.; Sun, L.; Chen, X.; Zhang, D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen. Res., 2013, 8(21), 2003-2014.
[152]
Harandi, A.A.; Ashrafi, F.; Tabatabaei, M. Efficacy and tolerability of MLC601 in patients with mild to moderate Alzheimer disease who were unable to tolerate or failed to benefit from treatment with rivastigmine. Br. J. Med. Med. Res., 2013, 3(2), 341.
[155]
Lee, J.H.; Jahrling, J.B.; Denner, L. Targeting Insulin for Alzheimer’s Disease: Mechanisms, Status and Potential Directions. J. Alzheimers Dis., 2018, 1-27.
[166]
Alam, J.; Blackburn, K.; Patrick, D. 3. Alam J, Blackburn K, Patrick D. Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38alpha to reverse synaptic dysfunction in early Alzheimer’s disease. J. Prev. Alzheimers Dis., 2017, 4(4), 273-278.
[186]
Singh, C. Trinity Laboratories Inc, assignee. Dextromethorphan hydrochloride. United States patent US, 2011, 623.
[213]
Park, JJ; Choi, SH; Kim, S Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease. Geriatr Gerontol. Int., 2017, 17(10), 1661-6-70.
[214]
Penhasi, A.; Gomberg, M. A specific two-pulse release of rivastigmine using a modified time-controlled delivery system: A proof of concept case study. J. Drug Deliv. Sci. Technol., 2018, 47, 404-410. http://dx.doi.org/10.1016/j.jddst.2018.08.009
[216]
Available at: https://www.nia.nih.gov/health/how-alzheimers-disease-treated